« Back to report listing

OVERVIEW

Cost:$2500

PUBLICATION DATE:Jan 2012

Therapeutic Class:CNA

Number of Pages:54

standard report icon

Comprehensive Landscape and Expert Opinions on the Treatment of Multiple Sclerosis

REPORT SUMMARY

This report examines the current opinions of experts in the field concerning MS treatment options. The report also reviews potential drug treatments in Phase III clinical trials. Combining key opinion leader input with a drug development pipeline (including key market drivers and challenges), the report provides readers with a comprehensive MS therapeutic landscape.


EXECUTIVE SUMMARY

Currently, in the United States there are approximately 400,000 people with MS; 200 more are diagnosed every week. Worldwide, MS is thought to affect more than 2.5 million people. The prevalence of MS is increasing in third world countries as well as in women. Women are 2 to 3 times more likely than men to be diagnosed. Symptoms of MS range from mild to severe, can be debilitating, and affect adults as well as children. The cause of MS is unknown and continues to be an active area of research. There is currently no cure for this disease. MS is very difficult to diagnose as it presents with symptoms similar to other neurological diseases.

There are currently several therapies available for treatment. Due to the high cost of current therapies, the invasive nature of the interferons (injectables), and the need for therapies that are more efficacious with better safety profiles, the MS space has many needs. There are several potential entrants into the space, including novel products, oral therapies, and treatments with a lower dosage frequency.

This report examines the current opinions of experts in the field concerning MS treatment options, while also reviewing potential drug treatments in Phase III clinical trials. Combining key opinion leader input with a drug development pipeline (including key market drivers and challenges) this report provides readers with a comprehensive MS therapeutic landscape. The MS market is likely to undergo significant changes as novel therapies enter the market and prices of current therapies are reduced. The growth of the market in the next few years is likely to increase exponentially.


TABLE OF CONTENTS

  • Chapter 1: Introduction
    • Key Drivers
      • Incidence and prevalence rate for MS increases
      • Technology is becoming more advanced
      • Biomarkers
      • Current treatments do not provide a cure
      • Current treatments have low compliance
      • Breakthroughs in the disease occur with first line treatment
      • There are no effective treatments for those patients beyond RRMS
      • Current therapies have a large price tag
    • Key Challenges
      • Diagnosis of MS is difficult
      • Treatment of patients
      • Long term safety profile of new treatments
      • Generics into the market in 2012/2013
  • Chapter 2: Current Treatments
    • Drug Profiles
      • Avonex
    • Subcutaneous Interferon Treatments
      • Rebif
      • Betaseron
      • Extavia
      • Copaxone
      • Tysabri
      • Gilenya
      • Ampyra
    • Cost of Current MS Drugs
  • Chapter 3: Pipeline
    • Near Term Phase III Entrants
      • Laquinimod
      • Lemtrada
      • BG-12
      • Teriflunomide
      • Zenapax 30
      • Cladribine
    • Treatment for other forms of MS
      • Novantrone
  • Chapter 4: MS Summary
  • Chapter 5: Transcripts

COMPANIES DISCUSSED

  • Biogen Idec
  • Elan
  • EMD Serono
  • Pfizer
  • Bayer
  • Novartis
  • Biogen Idec
  • Teva
  • Merck Serono
  • OSI
  • Novartis
  • Biogen Idec
  • Acorda

DRUGS DISCUSSED

  • Avonex
  • Rebif
  • Betaseron
  • Extavia
  • Tysabri
  • Copaxone
  • Novantrone
  • Gilenya
  • Ampyra